Fig. 3: Risk of second relapses resulted higher in patients carrying at diagnosis TP53 deletion or mutation, including double-hit events, as compared to patients carrying wild-type TP53. | Blood Cancer Journal

Fig. 3: Risk of second relapses resulted higher in patients carrying at diagnosis TP53 deletion or mutation, including double-hit events, as compared to patients carrying wild-type TP53.

From: Clonal and subclonal TP53 molecular impairment is associated with prognosis and progression in multiple myeloma

Fig. 3: Risk of second relapses resulted higher in patients carrying at diagnosis TP53 deletion or mutation, including double-hit events, as compared to patients carrying wild-type TP53.The alt text for this image may have been generated using AI.

Effect on PFS2 of a TP53 deletion as a single-hit (cut-off ≥10%) as detected by SNP array (p = 0.04, HR 1.71, 95% CI: 1.03–2.84); b TP53 deletion or mutation (VAF ≥ 5%) (p = 0.05, HR 1.62, 95% CI: 0.99–2.66); c coexistence of both deletions and mutations on TP53 (p = 0.02, HR 3.10, 95% CI: 1.18–8.17).

Back to article page